Carter Thorne, MD, Discusses Biosimilar Switching in Canada

Podcast

We sat down with Carter Thorne, MD, FRCPC, former president of the Canadian Rheumatology Association and chief of the Division of Rheumatology and director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Ontario, to discuss the current status of Canada’s comfort level with biosimilars and what he sees for the future of switching policies.

Welcome to Not So Different, a podcast from The Center for Biosimilars®. I’m your host, Assistant Editor Skylar Jeremias.

Although Canada has taken a different route than the United States in increasing uptake of biosimilars, the country faces plenty of opposition to these agents. This is due in part to policies to automatically switch patients from reference products to biosimilars in some provinces. The first of these policies became effective in British Columbia in 2019.

In addition to British Columbia, 4 other provinces are looking into developing their own switching policies. However, there is still much work to be done on educating physicians and patients on the safety and efficacy of biosimilars before more regulatory bodies feel comfortable enough to enact their own versions of these policies.

We sat down with Carter Thorne, MD, FRCPC, former president of the Canadian Rheumatology Association and chief of the Division of Rheumatology and director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Ontario, to discuss the current status of Canada’s comfort level with biosimilars and what he sees for the future of switching policies.

To learn more about Canadian switching policies, click here.

Related Videos
Ha Kung Wong, JD.
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Michael Kleinrock
Ian Henshaw
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2024 MJH Life Sciences

All rights reserved.